Education

1978-1980   Penn State University, University Park, PA --June 1978-August 1979, June 1980-August 1980

1981             B.S. in Science with highest distinction, Penn State University

1979-1983   Jefferson Medical College, Philadelphia, PA

1983   M.D.  Jefferson Medical College

Postdoctoral Training

1992-1995 Postdoctoral Biotechnology Fellow Laboratory of Human Carcinogenesis Curtis C. Harris, M.D., Chief National Cancer Institute, NIH, Bethesda, MD

1988-1991 Fellow, Division of Hematology/Oncology University of New Mexico Affiliated Hospitals Albuquerque, NM

1987          Chief Resident, Internal MedicineUniversity of New Mexico Affiliated Hospitals Albuquerque, NM

1983-1986 Intern and Resident, Internal Medicine University of New Mexico Affiliated Hospitals Albuquerque, NM

Board Certification

1991, 2001, 2011   American Board of Internal Medicine Subspecialty in Medical Oncology

1986   American Board of Internal Medicine

1984   National Board of Medical Examiners

Clinical Expertise

Gastrointestinal Cancers

Cancer Genetics (Familial Cancer Program)

Research

Dr. Greenblatt's research interests are in interpreting genetic variants in cancer susceptibility genes by using multiple lines of evidence (epidemiology, statistics, tumor pathology, evolution, structure, and function, computational algorithms). He has led projects that have integrated in vitro and in silico (computational) data to interpret genetic variation. Dr. Greenblatt’s current research activities involve interpretation of variants in the DNA mismatch Repair genes that are responsible for Lynch syndrome, the most common form of hereditary colorectal cancer.

Professional Societies

Human Genome Variation Society, President 2012 

American Association of Cancer Research

Alliance for Clinical Trials in Oncology

American Society of Human Genetics

American Society of Clinical Oncology

Collaborative Group of the Americas on Inherited Colorectal Cancer

Human Variome Project, Scientific Advisory Council 

International Society for Gastrointestinal Hereditary Tumors (InSiGHT), Variant Interpretation Committee

Vermont Medical Society

Publications

For a complete list of Marc Greenblatt's publications, please visit Google Scholar.

Drost M, Tiersma Y, Thompson BA, Frederiksen JH, Keijzers G, Glubb D, Kathe S, Osinga J, Westers H, Pappas L, Boucher KM, Molenkamp S, Zonneveld JB, van Asperen CJ, Goldgar DE, Wallace SS, Sijmons RH, Spurdle AB, Rasmussen LJ, Greenblatt MS, de Wind N, Tavtigian SV, A Functional Assay-Based Procedure to Classify Mismatch Repair Gene Variants in Lynch Syndrome, Genet Med, 2019, 21(7):1486-1496, PMID: 30504929 

Seifert BA, Jackson SA, McGlaughon J, Ritter DI, Roberts ME, Schmidt RJ, Thompson BA, Jimenez S, Trapp M, Lee K, Plon SE, Offit K, Berg JS, Stadler ZK, Zhang L, Greenblatt MS, Ferber MJ, Determining the clinical validity of hereditary colorectal cancer and polyposis susceptibility genes using the Clinical Genome Resource Clinical Validity Framework, Genet Med. 2019 Jul;21(7):1507-1516.

Dominguez-Valentin M, Sampson JR, Seppälä TT, ten Broeke SW, Plazzer JP., Nakken S, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, Balaguer F, Thomas H, Evans DG , Burn J, Greenblatt M, Hovig E, de Vos tot Nederveen Cappel WH, Sijmons RH, Bertario L, Tibiletti MG, Cavestro GM, Lindblom A, Della Valle A, Lopez-Koestner F, Gluck N, Katz L, Heinimann K, Vaccaro CA, Reinhard Bu¨ttner R, Görgens H, Holinski-Feder E, Morak M, Holzapfel S, Hüneburg R, von Knebel Doeberitz M, Loeffler M., Rahner N, Schackert HK, Steinke-Lange V, Schmiegel W, Vangala D, Pylvänäinen K, Renkonen-Sinisalo L, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Wadt K, Therkildsen C, Okkels H, Ketabi Z, Moreira L,Sánchez A, Serra-Burriel M, Pineda M, Navarro M, Blanco I, Green K, Lalloo F, Crosbie E, Hill J, Denton OG, Frayling IM., Rødland EA, Vasen H, Mints M, Neffa F, Esperon P, Alvarez K, Kariv R, Rosner G, Pinero TA, Gonzalez ML., Kalfayan P, Tjandra D, Macrae F, Möslein G., Mecklin JP, Nielsen M., Møller P. Cancer risks by gene, age and gender in 6,350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database, Genet Med, 2019, in press.  PMID: 31337882

Brnich SE, Abou Tayoun AN, Couch FJ, Cutting GR, Greenblatt MS, Heinen CD, Kanavy DM, Luo X, McNulty SM, Starita LM, Tavtigian SV, Wright MW, Harrison SM, Biesecker LG, Berg JS, Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework, Genome Medicine 2019, in press.

Drost M, Tiersma Y, Glubb D, Kathe S, van Hees S, Ramlal RPE, Thompson BA, Calléja F, Zonneveld JBM, Rasmussen LJ, Greenblatt MS, Lee A, Spurdle AB, Tavtigian SV, de Wind N, A comprehensive, functional analysis-based, procedure for the diagnostic assessment of MSH6 Variants in Lynch Syndrome, Genet Med 2019, in press.

Selected publications:

Hermel DJ, McKinnon WC, Wood ME, Greenblatt MS, Multi-gene Panel Testing for Hereditary Cancer Susceptibility in a Rural Familial Cancer Program, Familial Cancer 2016, Jul in press.  PMID: 27401692

Erten MZ, Fernandez LP, Ng HK, McKinnon WC, Heald B, Koliba CJ, Greenblatt MS, Universal versus Targeted Screening for Lynch Syndrome: Comparing Ascertainment and Costs Based on Clinical Experience, Dig Dis Sci, 2016 Oct; 61(10): 2887-95.  PMID: 27384051

denDunnen JT, Dagliesh R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, Roux A-F, Smith T, Antonarakis SE, Taschner PEM, HGVS Recommendations for the Description of Sequence Variants: 2016 Update, Hum Mutat. 2016 Jun;37(6):564-9. PMID: 26931183